NCT05417555 · RECRUITING

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

This trial tests whether Low-Intensity Focused Ultrasound Pulsation (LIFUP) — a non-invasive device that delivers gentle sound waves to a specific brain region — can boost memory-related brain activity in people with Mild Cognitive Impairment or mild Alzheimer's disease. Researchers will measure brain activity, memory test scores, and network connectivity using MRI. This is a Phase NA (feasibility or pilot) study, meaning the goal is to see whether the approach shows enough promise to study further. It is not a proven treatment.

Eligibility criteria

Inclusion Criteria
* Amnestic MCI or Mild Alzheimer's diagnosis
* Age 50-90
* English-speaking
* Ability to provide informed consent
* Normal or corrected-to-normal hearing and vision
Exclusion Criteria
GENERAL
* Participation in another clinical trial
* Active use of immunotherapeutic medications for cognition (Aduhelm, Leqembi, Kisunla)
* Moderate to Severe Alzheimer's
* Inability to provide informed consent
MRI-Related:
* Weight exceeding 275 pounds
* Pregnancy, suspicion of pregnancy, or attempting to become pregnant
* Claustrophobia
* Difficulties during previous MRIs
* Top permanent retainer (bottom only is okay), 5 or more non-removable gold-teeth, metal braces, top spacers, and/or palate expanders
* Any of the following implants: Cardiac Pacemaker, Aneurysm clips, Cochlear implants, Defibrillator, Electrodes or wires, Magnetically-activated device, Spinal cord stimulator, Infusion or insulin pumps, Implanted drug infusion device, Deep brain stimulation device
* Non-removable hairpieces, hairpiece extensions, and/or piercings
* Facial tattoos or permanent makeup
* Metal implants that are MR-incompatible, or where participant is unable to provide sufficient information to determine MR compatibility
* Previous injury by metallic foreign body (e.g., bullet, BB, shrapnel) where the object entered the body and participant lacks doctor's confirmation that it was fully removed
Medical:
* Diagnosis of one or more of the following neurological disorders: Parkinson's disease, Lou Gehrig's disease (ALS), Multiple sclerosis, Cerebral Palsy
* Diagnosis of one or more of the following genetic disorders: Cystic Fibrosis, Sickle Cell Disease
* Diagnosis of one or more of the following psychiatric disorders: Bipolar, Psychosis
* Psychiatric illness that has not been controlled for at least two months (if controlled >2 months, with or without medication, they are not exclusionary)
* Severe lung, liver, heart, and/or kidney disease/s (e.g., heart failure, liver failure, and etc...)
* Diagnosis of thyroid disorder or change of thyroid medication dose within the last 3 months
* Cancer treatment/s with chemotherapy and/or radiation to head and neck, or stage 4 (metastatic) cancer
* Autoimmune disorder or viral infection such as HIV, COVID 19, or hepatitis C that has caused current problems with cognition/memory
* History of substance abuse in the past year
* History of stroke (Transient ischemic attack / mini-stroke not exclusionary if symptoms lasted \<1 week)
* History of 2 or more seizures or diagnosis of epilepsy, unless the seizures occurred prior to age 5 alongside a fever.
* History of brain tumor, brain aneurysm, brain hemorrhage, or subdural hematoma (transient ischemic attack not exclusionary)
* Head injury that resulted in loss of consciousness lasting >30 minutes, cognitive issues lasting >18 months, and/or brain abnormalities visible in CT or MRI scan
* Uncontrolled high blood pressure or diabetes
* Heart attack within the last year

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2024-09-05

View full record on ClinicalTrials.gov

All APOE4 clinical trials